Prothya Biosolutions Netherlands B.V.

Prothya Biosolutions Netherlands B. V. is a Belgian company specializing in the development and manufacturing of plasma-derived medicinal products essential for critical healthcare needs. Prothya Biosolutions focuses on creating life-saving treatments through the isolation and purification of proteins from human blood plasma.

Established in 2021, the company is headquartered in Brussels, Belgium. The founder's history is not publicly detailed, and Prothya is noted to have participated in 2 significant deals with the most recent one occurring on August 12, 2025. Prothya Biosolutions specializes in the development and manufacturing of high-quality plasma-derived medicinal products aimed at addressing critical healthcare needs. Their core offerings involve the isolation and purification of proteins from human blood plasma, resulting in life-saving treatments primarily used in the fields of immunology and critical care.

These products are vital for patients with conditions that require immunoglobulins, clotting factors, or albumin, among others. Prothya's commitment to innovation is reflected in their advanced methodologies, enabling them to produce over 60 years of accumulated expertise. The company's client base primarily includes healthcare-oriented organizations across Europe, North America, and Asia, which utilize these essential therapies to improve patient outcomes. Prothya Biosolutions generates revenue through direct partnerships with healthcare providers and organizations, offering a range of plasma-derived medicinal products under its own brand.

The company engages in B2B transactions, establishing contracts with healthcare institutions that require consistent supplies of their therapies. Revenue stems from bulk orders structured around long-term agreements, ensuring a steady flow of products to clients who utilize them in critical care settings. Prothya's flagship products, including immunoglobulins and clotting factor concentrates, are sold through these established channels, serving a diverse array of end users, from hospitals to specialized clinics. The company emphasizes a partnership approach, fostering collaborative relationships that enhance the accessibility and efficacy of their life-saving treatments.

In August 2025, Accord Healthcare Limited, a portfolio company of Intas Pharmaceuticals Ltd. , ChrysCapital, Temasek Holdings, and Abu Dhabi Investment Authority, agreed to fully acquire Prothya Biosolutions Netherlands B. V. from Fortissimo Capital, Mesola Inversiones, OBF Investments, Biosolutions, LLC and EpsteinCap.

Financial terms of the transaction were not disclosed. This acquisition is expected to enhance Intas Pharmaceuticals' plasma research capabilities and business footprint. Prothya is strategically positioned to explore the launch of new plasma-derived products while expanding its market presence into regions such as Asia and North America by 2026.